Using Implanted Port Catheters for Chemotherapy in Liver Cancer
Author Information
Author(s): Hildebrandt Bert, Pech Maciej, Nicolaou Annett, Langrehr Jan M, Kurcz Jacek, Bartels Birgit, Miersch Alexandra, Felix Roland, Neuhaus Peter, Riess Hanno, Dörken Bernd, Ricke Jens
Primary Institution: Charité-Universitätsmedizin Berlin
Hypothesis
Can interventionally implanted port catheter systems (IIPCS) provide a safer and more effective method for delivering chemotherapy to patients with colorectal liver metastases compared to surgically implanted port catheter systems (SIPCS)?
Conclusion
HAI via interventionally implanted port catheters can be safely provided to patients with colorectal liver metastases and offers technical advantages over the surgical approach.
Supporting Evidence
- All patients in the IIPCS group had successful port implantation.
- The secondary failure rate was significantly higher with the surgical approach (50% vs. 17%).
- Mean port duration was significantly longer in the interventional group (19 months vs. 14 months).
- 77% of devices in the IIPCS group were functioning at 12 months compared to 50% in the SIPCS group.
Takeaway
Doctors used a new type of port to give medicine directly to the liver in cancer patients, and it worked better and was safer than the old method.
Methodology
41 patients were treated with IIPCS and compared to 40 historical patients treated with SIPCS, focusing on complications and port duration.
Potential Biases
The non-randomized design may introduce selection bias.
Limitations
The study was non-randomized and focused primarily on technical endpoints rather than oncological outcomes.
Participant Demographics
Patients had isolated liver metastases of colorectal cancer, with a mix of pre-treated individuals.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website